Long-Term Data Shows Feasibility of Adjuvant Trials in Prostate Cancer
This video examines long-term findings from a trial that tested ADT alone vs ADT plus chemotherapy as adjuvant therapy for patients with high-risk prostate cancer, including some surprising results and important takeaways.
In this video, L. Michael Glodé, MD, discusses long-term findings from a trial that tested 2 years of androgen-deprivation therapy (ADT) vs 2 years of ADT plus mitoxantrone and prednisone following radical prostatectomy in patients with high-risk prostate cancer. Glodé highlights some of the surprising results and important takeaways.
The trial, which began accrual in 1999, included 961 eligible patients but was stopped early due to a significant increase in cases of acute myeloid leukemia in the experimental arm. The 10-year overall survival rate was similar between the two groups (87% with ADT alone vs 86% with ADT plus chemotherapy).
Results of the study (abstract 2) were presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida.
![TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fbb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC")
